Peter Bains - Mereo Biopharma Non-Executive Independent Director

MREO
 Stock
  

USD 1.35  0.20  17.39%   

  Director
Mr. Peter Bains is NonExecutive Independent Director of the Company. He has over two decades of experience in the pharmaceutical industry encompassing strategic and operational leadership expertise across global geographies, functions and business segments. He is currently representative executive officer and chief operating officer of Sosei Group Corporationrationration, a Tokyo listed biotech company. It is expected that Mr Bains will become representative executive officer, president and chief executive officer upon approval by Soseis board of directors in June 2016 following the groups annual general meeting. Previously, he was chief executive officer of Syngene International, where he continues to be a nonexecutive director. He also currently serves as nonexecutive director for Phase4 Partners. He is also chairman of Fermenta Biotech, a subsidiary of DIL, a Mumbai listed company. Previously, he had a 23year career at GlaxoSmithKline, where he held multiple senior roles. Mr Bains received a BSc Combined in PhysiologyZoology from Sheffield University.
Age: 61    MBA    
44 33 3023 7300  https://www.mereobiopharma.com

Mereo Biopharma Management Efficiency

Mereo Biopharma Group has return on total asset (ROA) of (13.82) % which means that it has lost $13.82 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 34.85 %, meaning that it created $34.85 on every $100 dollars invested by stockholders. Mereo Biopharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is expected to rise to 0.14 this year. Return on Average Equity is expected to rise to 0.38 this year. Mereo Biopharma Assets Non Current are quite stable at the moment as compared to the past year. The company's current value of Assets Non Current is estimated at 34.35 Million. Goodwill and Intangible Assets is expected to rise to about 31.5 M this year, although the value of Total Assets will most likely fall to about 117.3 M.
The company currently holds 16.76 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Mereo Biopharma Group has a current ratio of 7.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Mereo Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Mereo Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mereo Biopharma Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mereo to invest in growth at high rates of return. When we think about Mereo Biopharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 10 records

DIRECTOR Since

Diane GreeneAlphabet Cl A
2019
Kavitark ShriramAlphabet Cl A
1998
Robin WashingtonAlphabet Cl A
2019
John DoerrAlphabet Cl A
2016
Ann MatherAlphabet Cl A
2005
Roger FergusonAlphabet Cl A
2016
Paul OtelliniAlphabet Cl A
2004
Alan MulallyAlphabet Cl A
2014
John HennessyAlphabet Cl A
2018
Shirley TilghmanAlphabet Cl A
2005
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people. Mereo Biopharma Group (MREO) is traded on NASDAQ Exchange in USA. It is located in One Cavendish Place and employs 49 people. Mereo Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification.

Mereo Biopharma Group Leadership Team

Elected by the shareholders, the Mereo Biopharma's board of directors comprises two types of representatives: Mereo Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mereo. The board's role is to monitor Mereo Biopharma's management team and ensure that shareholders' interests are well served. Mereo Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mereo Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Peter Bains, Non-Executive Independent Director
Kunal Kashyap, Non-Executive Director
Deepa Pakianathan, Non-Executive Director
Paul Blackburn, Non-Executive Independent Director
Alastair MacKinnon, Chief Medical Officer and Co-Founder
Michael Wyzga, Non-Executive Director
Richard Jones, CFO, Executive Director
Richard Francis, Head of Pharmaceutical Development
John Richard, Head of Corporate Development and Co-Founder
Charles Sermon, Co-Founder, General Counsel, Secretary
Denise ScotsKnight, CEO, Co-Founder, Executive Director
Peter Fellner, Independent Non-Executive Chairman of the Board
Anders Ekblom, Non-Executive Independent Director

Mereo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mereo Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Mereo Biopharma Investors Sentiment

The influence of Mereo Biopharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Mereo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Mereo Biopharma's public news can be used to forecast risks associated with investment in Mereo. The trend in average sentiment can be used to explain how an investor holding Mereo can time the market purely based on public headlines and social activities around Mereo Biopharma Group. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Mereo Biopharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Mereo Biopharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Mereo Biopharma's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Mereo Biopharma.

Mereo Biopharma Implied Volatility

    
  306.64  
Mereo Biopharma's implied volatility exposes the market's sentiment of Mereo Biopharma Group stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Mereo Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Mereo Biopharma stock will not fluctuate a lot when Mereo Biopharma's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mereo Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mereo Biopharma's short interest history, or implied volatility extrapolated from Mereo Biopharma options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Mereo Biopharma Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
134.5 M
Return On Assets
-0.14
Return On Equity
0.35
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.